Use of alloreactivity to generate in vivo anti-leukemic responses (46.48)
| Autor: | Loren Fast, John Reagan, Peter Quesenberry |
|---|---|
| Rok vydání: | 2012 |
| Předmět: | |
| Zdroj: | The Journal of Immunology. 188:46.48-46.48 |
| ISSN: | 1550-6606 0022-1767 |
| Popis: | A previous clinical trial demonstrated that infusion of haploidentical G-CSF mobilized WBC (1 - 2 x 10^8 cells/kg) into patients with refractory hematological malignancies (100 cGy irradiation) resulted in a high frequency of anti-leukemic responses including some complete responses despite a lack of detectable donor cell persistence beyond two weeks. Beyond a cytokine storm, no effector mechanisms were defined. It is possible that alloreactive responses were either capable of directly attacking the leukemic cells or reactivating the patient’s anti-leukemic effector cells that were already present via cross-reactivity. PBMNC were obtained from the blood of newly diagnosed leukemic patients, and separated into CD3- and CD3+ populations. The patient’s CD3+ cells were used as responder cells in a mixed lymphocyte culture and stimulated with mitomycin C treated patient’s CD3- cells or PBMNC from allogeneic normal donors chosen at random. On day 7, the effector cells were collected and tested for their ability to lyse 51Cr labeled patient CD3- cells. The results showed that the patient’s CD3+ cells stimulated with allogeneic PBMNC were able to generate anti-leukemic responses in a stimulator dependent fashion. Thus, this assay may be useful for predicting which donor would be best for patients receiving cellular immunotherapy and may also be useful for the defining the anti-leukemic effector cells that are present with this form of cellular immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|